#USA #Vienna #Nutraceuticals #Freedom International #Elitepharm

Freedom International Group's Strategic Move into the Nutraceutical Sector

An Overview of the Investment

On February 17, 2025, the Freedom International Group (FIG) announced a significant strategic investment in Elitepharm Laboratories, positioning itself as a major shareholder in this innovative company. With a primary focus on sectors such as technology, finance, health, and wellness, FIG manages assets exceeding 2.5 billion euros, making this move a pivotal part of its growth strategy.

Elitepharm, based in France, is renowned for its role in the formulation and manufacturing of customized dietary supplements. As a key player, the company caters to a broad range of projects, from small-scale to large-scale production. This partnership was forged under the leadership of FIG President and CEO Narek Sirakanyan, who believes this strategic investment is fundamental for growth within the health sector.

The Vision Behind the Partnership

Narek Sirakanyan articulated a clear vision for this partnership: "Freedom is making a strategic investment in the health sector, supported by our AI-driven software that enhances supplement formulations." This statement underlines the role of technology in shaping the future of nutritional science. Additionally, he highlighted France as an optimal location for supplement manufacturing, emphasizing the accessibility of active ingredients and adherence to stringent industry regulations.

To enhance product efficiency and reliability, FIG plans to leverage the expertise of its IT subsidiary, Sessia, to invest in AI technologies. These innovations are expected to streamline operations by yielding swifter and more precise outcomes from focus groups.

The Road Ahead for Elitepharm

Through this alliance, which includes cooperation with Elitepharm’s President Gérard Strauch, FIG aims to optimize production processes and increase market presence. Elitepharm currently produces around 25 million capsules monthly, with aspirations to double this output as part of the ambitious growth plan targeting a revenue goal of 50 million euros by 2029.

Strauch, drawing from his extensive experience in the supplement market, has been instrumental in positioning Elitepharm as a leader known for scientific accuracy and anticipation of market trends. Under his guidance, the company’s structure has been tailored to meet the evolving demands of the industry, emphasizing quality and flexibility.

Strategic Objectives for Expansion

The partnership aims to accelerate Elitepharm's commercial and industrial growth through several strategic objectives:
1. Enhancement and Acquisition of Facilities: Elitepharm plans to upgrade its existing infrastructure and acquire new production sites to cater to increasing international demand.
2. Vertical Integration: By investing in farms that specialize in organic raw materials, Elitepharm will ensure quality control and traceability of its ingredients, solidifying its supply chain.
3. Broadening Product Portfolio: The company intends to expand its product offerings by collaborating with experts, bolstering its scientific team, and pursuing strategic acquisitions.

Sirakanyan noted, "The acquisition of Elitepharm by FIG is a crucial step in our vertical integration strategy, which will continue with further acquisitions in agricultural operations supplying biological active ingredients to Elitepharm."

Aiming for European Leadership

This strategic investment is set to elevate Elitepharm's prominence in the European market. As Strauch stated, "We share a strategic vision, convinced that innovation and industrialization are the keys to success. We are prepared to explore new markets." This partnership signifies both companies' commitment to building a robust and sustainable industry model dedicated to promoting health and wellness across Europe.

In conclusion, with FIG's influential backing, Elitepharm Laboratories is on a poised trajectory for transformative growth within the nutraceutical sector, promising an exciting future for health-conscious consumers and stakeholders alike.